Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2026-08-04
Dear Investor,
Please find attached a press release from our partner Nurix Therapeutics:
https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-first-patient-enrolled/
Do not hesitate to contact us for any further questions.
With best regards,
| Roche Investor Relations | |
| Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com | Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
| Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com | |
| Investor Relations North America | |
| Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
InvestorsInvestor updates
stay updated
get the latest news and updates to your inbox.